Moderna, Inc.

NASDAQ Global Select
Back to all articles
Bullish +75

Moderna stock heads into the open after a 12.27 percent gain

AI-generated analysis

📈 Moderna stock closed at USD 172.94, marking a significant 12.27 percent gain that far exceeded the broader Nasdaq Composite rise.

🚀 The share price hit a new 52-week high of USD 176.86 during the session with volume reaching nearly 21 million shares.

🔬 Three abstracts on intismeran autogene were accepted for presentation at the ESMO Congress 2026 in Madrid.

📅 Detailed Phase 3 melanoma results for the drug are scheduled to be presented starting October 24, 2026.

🏥 The congress will take place from October 23 through October 27, 2026, at a major medical venue in Madrid.

Bullish Signals
  • Moderna stock surged 12.27 percent to close at USD 172.94, significantly outperforming the Nasdaq Composite.
  • The share price reached a new 52-week high of USD 176.86, indicating strong bullish momentum.
  • Three abstracts on intismeran autogene were accepted for presentation at the prestigious ESMO Congress 2026.
  • Upcoming detailed Phase 3 melanoma results are scheduled for presentation in late October, offering a potential catalyst.
Full Analysis
Moderna Inc. (MRNA) shares surged 12.27 percent to close at USD 172.94 on September 21, 2026, significantly outperforming the Nasdaq Composite's 2.26 percent gain. The stock traded in a range between USD 154.04 and USD 176.86, reaching a new 52-week high with trading volume of approximately 20.9 million shares. The rally followed news that three abstracts regarding the drug intismeran autogene were accepted for presentation at the upcoming ESMO Congress 2026 in Madrid. Detailed Phase 3 melanoma results for the candidate are scheduled to be presented during the congress, which runs from October 23 through October 27, 2026. This positive market reaction highlights investor interest in Moderna's oncology pipeline progress, specifically the potential approval or data readout of its melanoma treatment. The stock performance underscores the material impact of upcoming clinical trial presentations on the company's valuation and market sentiment.